Answers are grounded in this paper and cite their sources.
Sildenafil, approved for pulmonary arterial hypertension (PAH), has a recommended adult dose of 20 mg TID, with a previously approved 5-mg TID dose by the US Food and Drug Administration. Safety concerns arose because of common off-label use of higher doses, particularly after pediatric data linked higher doses to increased mortality. To assess this, the Food and Drug Administration mandated a study evaluating the effects of various sildenafil doses on mortality in adults with PAH.
No takes yet. Share an insight, caveat, or question.
Hoeper et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: